Safety questions linger as Pfizer preps Duchenne gene therapy for final test

Pfizer is adding fresh details to a growing body of evidence suggesting that gene therapy might help change the trajectory of Duchenne muscular dystrophy, a deadly genetic disease with no cure.

New study results from Pfizer, to be presented Friday at the American Society of Gene and Cell Therapy's yearly meeting, come with important caveats, however.